Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Feb 3;18(4):1425.
doi: 10.3390/ijerph18041425.

What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report

Morgane Guillou-Landreat  1   2   3 , Antoine Dany  2 , Gaëlle Challet-Bouju  1   4 , Edouard Laforgue  1   4 , Juliette Leboucher  4 , Jean Benoit Hardouin  1 , Caroline Victorri-Vigneau  1   5 , Marie Grall-Bronnec  1   3   4
Affiliations
Multicenter Study

What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report

Morgane Guillou-Landreat et al. Int J Environ Res Public Health. .

Abstract

(1) Background: Opioid use disorder (OUD) is a complex condition that can require long-term treatment. Pharmacological therapy for OUD involves treatment with opioid agonists (OMT) tailored to individual profiles. The aim of our study in daily clinical practice was to compare the profiles of patients treated with methadone (MTD) and those using buprenorphine (BHD or BHD-naloxone-NX). (2) Methods: A cross-sectional multicentre study explored the psychological, somatic and social profiles of patients with Opioid Use Disorder (OUD) following Opioid Maintenance Treatment (BHD, BHD/NX, or MTD). Descriptive and comparative analyses were performed. (3) Results: 257 patients were included, a majority were men using heroin. A total of 68% (178) were on MTD, 32% (79) were on BHD. Patients with MTD were significantly more likely to report somatic damage, and more likely to be younger and not to report oral or sublingual use as the main route for heroin or non-medical opioids. (4) Conclusions: In daily clinical practice, somatic damage was significantly more severe among MTD patients. Age and route of administration also differed, and our results could raise the issue of the type of OMT prescribed in case of non-medical use of prescribed opioids. These hypothesis should be confirmed in larger studies.

Trial registration: ClinicalTrials.gov NCT01847729.

Keywords: buprenorphine; daily clinical practice; methadone; opiate medication treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders (MILDECA, University Paris 13, France) had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

    1. Hasin D.S., O’Brien C.P., Auriacombe M., Borges G., Bucholz K., Budney A., Compton W.M., Crowley T., Ling W., Petry N.M., et al. DSM-5 criteria for substance use disorders: Recommendations and rationale. Am. J. Psychiatry. 2013;170:834–851. doi: 10.1176/appi.ajp.2013.12060782. - DOI - PMC - PubMed
    1. Paulozzi L.J., Zhang K., Jones C.M., Mack K.A. Risk of adverse health outcomes with increasing duration and regularity of opioid therapy. J. Am. Board. Fam. Med. 2014;27:329–338. doi: 10.3122/jabfm.2014.03.130290. - DOI - PMC - PubMed
    1. Dematteis M., Auriacombe M., D’Agnone O., Somaini L., Szerman N., Littlewood R., Alam F., Alho H., Benyamina A., Bobes J., et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: A European consensus. Expert Opin. Pharmacother. 2017;18:1987–1999. doi: 10.1080/14656566.2017.1409722. - DOI - PubMed
    1. Landreat M.G., Rozaire C., Guillet J.Y., Vigneau C.V., Le Reste J.Y., Bronnec M.G. French Experience with Buprenorphine: Do Physicians Follow the Guidelines? PLoS ONE. 2015;10:e0137708. - PMC - PubMed
    1. Fatseas M., Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr. Psychiatry Rep. 2007;9:358–364. doi: 10.1007/s11920-007-0046-2. - DOI - PubMed

Publication types

Associated data